A Preliminary Cost-Effectiveness Analysis of Low Dose Rivaroxaban Versus Placebo for the Prevention of Stroke and Cognitive Impairment in Non-Valvular Atrial Fibrillation Patients at Low Risk of Stroke

Autor:	Gisèle Nakhlé
Rok vydání:	2021
Předmět:	medicine.medical_specialty Rivaroxaban business.industry Low dose Non valvular atrial fibrillation Cost-effectiveness analysis medicine.disease Placebo Internal medicine medicine Cardiology Cognitive impairment business Stroke medicine.drug
Zdroj:	JCVM. 7:1-17
DOI:	10.17303/jcvm.2021.7.204
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::3d1c18434ce4b77fd368facd797011e3 https://doi.org/10.17303/jcvm.2021.7.204 Zobrazit plný text záznamu